Welcome to our dedicated page for Verrica Pharmaceuticals SEC filings (Ticker: VRCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Verrica Pharmaceuticals Inc. (VRCA) SEC filings page on Stock Titan aggregates the company’s official submissions to the U.S. Securities and Exchange Commission, providing investors with direct access to its regulatory and financial disclosures. Verrica is a Nasdaq-listed dermatology therapeutics company focused on YCANTH® (VP-102) for molluscum contagiosum and common warts, and VP-315 for non-melanoma skin cancers, and its filings reflect the evolution of these programs and the company’s capital structure.
Through Verrica’s Forms 8-K, investors can track material events such as private placement financings of common stock and warrants, amendments to collaboration and license agreements with Torii Pharmaceutical Co. Ltd., reverse stock split actions, and notices and resolutions related to Nasdaq listing compliance. These current reports also incorporate press releases announcing quarterly financial results, where Verrica details product revenue from YCANTH, license and collaboration revenue from Torii, operating expenses, and net income or loss.
Filings related to collaboration amendments describe key economic terms, including milestone payments tied to YCANTH approvals in Japan, cost-sharing for the global Phase 3 program in common warts, and technology transfer and royalty arrangements for YCANTH applicator manufacturing. Capital markets filings outline the terms of private investments in public equity, including pre-funded warrants, Series C warrants, registration rights agreements and the intended use of proceeds, such as repayment of credit facilities and funding operations.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight the most important elements of each filing, helping readers quickly understand how new agreements, financings, clinical milestones or listing actions may relate to Verrica’s dermatology and dermatologic oncology strategy. Users can review real-time updates from EDGAR, monitor unregistered sales of equity securities, and connect financial disclosures to the company’s ongoing development of YCANTH and VP-315.
Verrica Pharmaceuticals files its annual report detailing progress in commercializing YCANTH and advancing its dermatology pipeline. YCANTH, the first FDA-approved treatment for molluscum contagiosum, was launched in the U.S. in 2023, supported by a roughly 40-person specialty sales force and coverage for about 250 million U.S. lives.
The company is pursuing a follow-on indication for common warts, with a global Phase 3 program underway and cost-sharing through a collaboration with Torii Pharmaceutical in Japan. It estimates over 6 million U.S. molluscum patients and about 22 million with common warts, each representing more than $1 billion in potential U.S. market opportunity.
Verrica is also developing VP-315, an oncolytic peptide for basal cell carcinoma. Phase 2 data showed complete histologic clearance in about 51% of tumors and an objective response rate of 97%, and FDA end-of-Phase 2 feedback supports an efficient Phase 3 path using two placebo-controlled studies.
Verrica Pharmaceuticals reported a strong turnaround in 2025, driven by YCANTH and partnerships. Total revenue rose to $35.6 million in 2025 from $7.6 million in 2024, with YCANTH net product revenue up 130% to $15.3 million. YCANTH dispensed applicator units nearly doubled to 51,296, reflecting growing demand.
Selling, general and administrative expenses fell by over 40%, helping shrink the GAAP net loss to $17.9 million from $76.6 million. The company ended December 31, 2025 with $30.1 million in cash and cash equivalents, no outstanding debt, and expects its cash runway to extend into the first quarter of 2027. Verrica is advancing VP‑315 toward a Phase 3 program in basal cell carcinoma in 2026 and progressing Phase 3 development of YCANTH for common warts, while preparing a European Union approval filing path for YCANTH without additional clinical studies.
Verrica Pharmaceuticals Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 439,657 shares, representing 4.99% of the outstanding common stock.
The filing states the reported shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital exercises shared voting and dispositive power; the Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement. The joint filing is signed by Steven Boyd on 02/17/2026.
BKB Growth Investments, LLC reported its beneficial ownership of derivative securities of Verrica Pharmaceuticals Inc. through an amended ownership statement. The filing lists Series B Warrants, immediately exercisable, for 224,719 shares of Verrica common stock at an exercise price of $13.35 per share, expiring on 11/22/2029.
The warrants include a cap that prevents exercises that would push BKB Growth’s beneficial ownership above 19.99% of Verrica’s outstanding common stock after the exercise. The amendment explains that the original exercise price did not reflect Verrica’s 1-for-10 reverse stock split that took effect on July 24, 2025.
Affinity Asset Advisors, LLC and Michael Cho have filed an amended Schedule 13G reporting a passive ownership stake in Verrica Pharmaceuticals Inc. They report beneficial ownership of 884,172 shares of Verrica common stock, including 176,834 shares issuable upon exercise of warrants, representing approximately 5.5% of the company’s common stock.
The securities are held directly by Affinity Healthcare Fund, LP, for which Affinity Asset Advisors acts as investment manager. The reporting persons state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Verrica.
BKB Growth Investments, LLC filed an initial ownership report showing a significant stake in Verrica Pharmaceuticals Inc.. As of 11/25/2025, the entity beneficially owns 3,348,372 shares of Verrica common stock directly.
BKB Growth Investments, LLC also holds Series B warrants for 224,719 shares at an exercise price of $1.335 per share, expiring on 11/22/2029, and Series C warrants for 687,690 shares at $6.315 per share, expiring on 11/25/2030. The warrants are immediately exercisable but include a 19.99% beneficial ownership cap, limiting exercise if it would push the holder above that ownership level.
Verrica Pharmaceuticals Inc. is registering up to 14,756,230 shares of common stock for resale by existing stockholders under a shelf registration statement.
The Resale Shares consist of 6,499,826 already issued shares, up to 5,305,164 shares issuable upon exercise of pre-funded warrants, and up to 2,951,240 shares issuable upon exercise of common warrants that were sold in a November 2025 private placement.
Verrica will not receive proceeds from stockholder resales, but would receive cash if the warrants are exercised at $0.0001 per pre-funded warrant share and $6.315 per common warrant share. The company focuses on dermatology therapeutics, including its FDA-approved YCANTH (VP-102) for molluscum contagiosum, and its auditors have previously noted substantial doubt about its ability to continue as a going concern.
Verrica Pharmaceuticals Inc. (VRCA) reported an insider purchase by its Chief Medical Officer. On 11/25/2025, the CMO acquired 2,357 shares of common stock in an open market purchase at a price of $4.2425 per share, and now directly owns 2,357 common shares.
The filing also reports a derivative transaction involving a Series C warrant with an exercise price of $6.315. The warrant covers 589 shares of common stock, is immediately exercisable, and expires on 11/25/2030. The securities were purchased as part of 2,357 investment units, each consisting of one share of common stock and a Series C warrant for one fourth of a share. The warrant includes a 9.99% beneficial ownership limitation, preventing exercises that would push the holder above that ownership level.
Verrica Pharmaceuticals Inc. (VRCA) reported an insider purchase by its Interim CFO. On 11/25/2025, the executive bought 3,536 shares of common stock at $4.2425 per share, bringing their directly held common stock to 8,962 shares after the transaction.
The filing also reports acquisition of 884 Series C warrants with an exercise price of $6.315 per share, exercisable immediately until 11/25/2030, each warrant linked to common stock. All security amounts reflect a 1-for-10 reverse stock split effective July 24, 2025. The Series C warrants include a 9.99% beneficial ownership cap, limiting how many shares can be obtained through exercise relative to the company’s outstanding common stock.
Verrica Pharmaceuticals Inc. (VRCA) disclosed that its Chief Operating Officer filed a Form 4 reporting the purchase of 10,000 shares of common stock on 11/25/2025 at $4.2425 per share through investment units.
Each unit also included a Series C warrant, giving the right to buy one fourth of a share, resulting in warrants exercisable for 2,500 shares of common stock at an exercise price of $6.315, expiring on 11/25/2030. Following the transaction, the officer beneficially owned 21,000 shares of common stock and 2,500 Series C warrants. The warrants are immediately exercisable but contain a 9.99% beneficial ownership limitation, preventing exercises that would push the holder’s ownership above that level. The numbers reflect a 1-for-10 reverse stock split effective July 24, 2025.